<DOC>
	<DOCNO>NCT02446652</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combination TRANSKRIP ® v placebo plus Carboplatin/Paclitaxel first line treatment patient recurrent-persistent cervical cancer .</brief_summary>
	<brief_title>Evaluation TRANSKRIP ® Plus Chemotherapy Recurrent-Persistent Cervical Cancer</brief_title>
	<detailed_description>HYPOTHESIS : It estimate add TRANSKRIP ® chemotherapy increase occur survival least 3.6 month superior compare patient receive QT ( 17.9 month TRANSKRIP plus QT 14.3 month QT , i.e . 20 % difference ) . Sample size : Data GOG ( Gynecologic Oncology Group ) 240 study use define 36 month survival rate 39.5 % control group . Losses 20 % , 95 % α , 80 % β , among group 1 ratio well 20 % survival experimental group consider . From , 230 include block 10 . Study overview : In patient meet inclusion criterion inform consent oral write grant , accept screen test make determine exclusion criterion ( CAT , laboratory ) . If meet criterion , patient assign follow treatment group : Group A ( 115 patient ) : TRANSKRIP® ( Hydralazine : 1 oral tablet every 24 hour , 182 mg rapid acetylators , 83 mg low acetylators Magnesium valproate : orally 30 mg/K weight every 8 hour ) start 1 week prior first day QT Carboplatin base ( 5 area curve ( AUC ) 1hour/day 1 ) plus Paclitaxel ( 175 175mg/m2/body surface ( BS ) 3hour/day 1 ) every 21 day 6 cycle . Group B ( 115 patient ) : Placebo ( orally ) start 1 week first day QT Carboplatin base ( 5 AUC 1hour/day 1 ) plus Paclitaxel ( 175 175mg/m2/BS 3hour/day 1 ) every 21 day 6 cycle . Patients include study conduct determine acetylator genotype polymerase chain reaction ( PCR ) sequence N-acetyltransferase 2 ( NAT2 ) gene , blood sample send central laboratory CIDAT S.A de C.V. Those slow acetylation result receive 83 mg/day Hydralazine plus 30 mg/Kg/day magnesium Valproate , patient fast acetylation result receive 182 mg/day Hydralazine plus 30 mg/Kg/day magnesium Valproate . Assigning patient : Randomization automatically generate computer randomization program ; list generate Contract Research Organization ( CRO ) hire study . The flask label Alpharma Manufacturing Department , random list identifies treatment every patient receive . Dose adjustment : All patient , previous chemotherapy administration , absolute neutrophil count &gt; 1500/µL platelet great 100,000/µL . If small number , treatment delay 1-2 week , achieve level . There wo n't dose adjustment chemotherapy . The chemotherapy dosage exceed initial dose calculation , unless patient weight change great 10 % require new dose calculation . A patient take drug 6 week since last treatment discontinue study . In case renal toxicity grade 3-4 , dosage carboplatin decrease 50 % . Dose reduction magnesium Valproate : If patient show somnolence grade 3 and/or ataxia grade 3 magnesium valproate suspend 3 day toxicity least grade 2 restart 20 mg/Kg . If 7 day somnolence grade 3 present increase 30 mg/Kg continue dose end study . If toxicity grade 3 resubmitted patient continue 20 mg/Kg end study . Dose reduction hydralazine : If patient show hypotension grade 3 , hydralazine suspend 3 day toxicity least grade 2 restart 50 % dose . If 7 day hypotension grade 3 presented increase 100 % dose continue dose end study . Procedures No 14 day initiation study drug , state disease form every patient evaluate following procedure : Medical history physical examination , Evaluation performance status ( ECOG scale ) , complete blood count ( CBC ) , Blood chemistry , Liver Function test ( LFT ) , Electrolytes , antinuclear antibody , Measurement palpable visible lesion , well determine image study compute tomography abdomen , thorax pelvis , Quality life questionnaire apply know basal state . At begin cycle : Medical history physical examination , Evaluation performance status ( ECOG scale ) , CBC , Blood chemistry , LFT , Electrolytes , antinuclear antibody , Hydralazine level valproic acid blood ( every 2 cycle ) , Toxicity evaluation establish criterion National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE V.3.0 ) . At end 3 6 cycle : Medical history physical examination , Evaluation performance status ( ECOG scale ) , CBC , Blood chemistry , LFT , Electrolytes , antinuclear antibody , Measurement palpable visible lesion , well determine image study compute tomography , Quality life questionnaire ( QLQ ) Cx-30 C-24 apply . Follow visit post-treatment every 3 month first 2 year , every 4 month third year , every 6 month fourth year later annually progression . During period Clinical History physical examination , assessment performance status , weight tumor lesion measurement physical examination image study obtain . CBC , Blood chemistry , LFT , electrolytes antinuclear antibody . Relapse , progression recurrence date . Quality life evaluate every 6 month follow complete 2 year start patient study . Patients participate study period prior treatment QT ( Carboplatin plus paclitaxel ) administration , experimental treatment TRANSKRIP® v Placebo suspend . Patients may withdraw study progression disease , intolerable toxicity , withdrawal consent patient investigator decision suspend participation patient study . In case suspend treatment , patient continue monitor non-protocol treatment treatment service . Efficacy criterion . The measure tumor ( ) define : Dimensionally measurable : The minimum size lesion considerable measurable 10 mm cut scanner 5mm 20mm high cut 5mm . A maximum 5 blank lesion organ and/or 10 total lesion identify . The sum maximum diameter lesion consider basal measure sum maximum diameter number use categorize answer . Unidimensionally measurable disease , lesions previously irradiate field , ascites , pleural effusion , bone , blastic mixed metastasis abdominal mass palpate measure shall consider measurable . To determine disease status study evaluate RECIST criterion . Clinical Adverse Events : Initially , staff study site interrogate patient write occurrence nature condition ( ) presentation preexistent condition ( ) . During study , staff interrogate patient write change preexistent condition ( ) and/or occurrence nature adverse event . All adverse event report regulatory agency appropriate pharmaceutical company accord local regulation . The staff study site report local regulatory body ( COFEPRIS respective committee National Cancer Institute ) , severe adverse event possibly relate study drug include : death , initial prolonged hospitalization , lay life threatening , severe permanent disability congenital anomaly . Patient substitution : It consider replaceable , patient randomize , reason receive dos Transkrip v placebo , affect trust power sample . Statistical analysis : All patient receive first cycle chemotherapy study evaluate safety . All patient meet histological diagnosis cancer , presence dimensionally measurable disease evaluation compute axial tomography ( CAT ) and/or Magnetic Resonance Imaging ( MRI ) third cycle evaluate efficacy . All confidence interval build level significance α = 0.05 ( Confidence level 95 % ) . One interim analysis expect one final analysis , first one include first 115 patient upon completion QT , final analysis expect 19 month last patient include . Intention analysis treatment patient include protocol meet criterion analysis carry . Processing analysis data base make Statistical Package Social Sciences ( IBM SPSS ) version 19.0 ® Microsoft . The demographic , clinical , treatment disease characteristic , analyze , descriptive statistic : measure central dispersion tendency : range , measure , median , mode , standard deviation , proportion ratios . Global Survival . It consider initial event subject inclusion study final event death . Survival time estimate parametric estimator Kaplan-Meier . Variances confidence interval estimate . Survival curve compare logrank test , consider bilateral test , significance level 95 % . Format Cox regression apply evaluate influence control variables survival time . Also survival time calculate consider initial event disease diagnose progression . Objective Response : parameter nominal ordinal scale Chi square test Fisher exact use . For quantitative variable interval T Student test use homogeneity . Toxicity : incidence adverse effect estimate , well frequency severity , laboratory value treatment . Frequency abnormal laboratory value estimate . Quality life : The linear transformation data perform obtain value scale 0-100 . In case miss data , calculation gross score numerator denominator , make take account item response . Thus avoid value affect extremes . Baseline analysis group obtain mean standard deviation median interquartile range , analysis data normality Kolmogorov-Smirnov take place . The bivariate analysis evaluate student test independent sample data parametric Mann Whitney test nonparametric data . With alpha 0.05 two-tailed . Besides intragroup longitudinal analysis perform monitor change quality life % change first second assessment bivariate analysis use paired Wilcoxon . With alpha 0.05 two-tailed . Progression free survival : It consider initial event subject inclusion study final event progression disease . Survival time estimate parametric estimator Kaplan-Meier . Variances confidence interval estimate . Survival curve compare logrank test , consider bilateral test , significance level 95 % . Format Cox regression apply evaluate influence control variables survival time .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Operating status ECOG : 02 Negative pregnancy test reproduction potential zero , determine either surgery , radiation menopause , mitigate use approve contraceptive method ( IUD hormonal contraceptive study least 3 month study ) . Patients histological diagnosis persistent/recurrent cervical cancer , local and/or systemic , disease measurable physical examination TAC . REQUIRED confirmation biopsy recurrence , persistence : lesion single , less 2 cm and/or sharp edge . Chemoradiotherapy pelvis pelvis plus extended field ( may receive concomitant chemotherapy radiosensitizer ) provide within 90 day last application secondary radiation acute effect disappear . Hemoglobin equal great 9 g/L . ( allow transfusion prior treatment reach hemoglobin level ) . Leukocytes great equal 4000/mm3 . Platelets equal great 100 000 mm3 . Hepatic : Total bilirubin 1.5 time normal value , albumin equal great 2 : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) low equal 2.5 time regular superior limit . Renal : Normal creatinine . If high , extent debugging must great 60 mL/min . With exception alopecia , patient resolution acute toxic effect prior surgery , radiotherapy chemotherapy , effect qualify accord Common Toxicity Criteria ( CTC version 3.0 ) National Cancer Institute ( NCI ) , within limit show laboratory parameter mention . Be willing able comply program visit , treatment plan laboratory test . The ability understand nature study give report write consent . Small cell and/or neuroendocrine cervical cancer . History allergy hydralazine , magnesium valproate sulfa . Any disease collagen present ( Systemic Lupus Erythematosus ( SLE ) , Rheumatoid arthritis ( RA ) , etc ) , history . Recent past condition symptomatic postural hypotension diagnose clinician . Secondary heart failure aortic stenosis condition vasodilator contraindicate . Recent past condition active disease central nervous system , include seizure . Previous current use magnesium valproate and/or anticonvulsive . Pregnant patient nursing . Prior cancer within last 5 year presence second primary tumor ( except carcinoma cervix situ basal cell carcinoma skin adequately treat ) . Use research agent month prior enrollment study . Serious concomitant systemic disorder incompatible study discretion investigator . Recently receive another oncospecific treatment research . The recently previously diagnose hypertension control antihypertensive combination ( provide include hydralazine ) WO N'T exclusion criterion . Criteria Treatment Interruption A patient discontinue study follow circumstance . If evidence disease progression . Unacceptable toxicity . If clinician considers change therapy best interest patient . If patient request discontinuation . If patient get pregnant use adequate birth control ( patient able conceive ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Advanced cervical cancer</keyword>
	<keyword>Epigenetic therapy</keyword>
	<keyword>Randomized phase III</keyword>
</DOC>